Publication date:	2003-07-10	MO03055475 (A1)
Inventor:	KERC JANEZ (SL); HUMAR VLASTA (SL)	WO03055475 (A1)
Applicant:	LEK PHARMACEUTICALS D D (SL); KERC JANEZ (SL); HUMAR VLASTA (SL)	
011611	(SE), HOWAR VEACTA (SE)	Cited documents:
Classification:		D = 55.4007007
international:	A61K9/20; A61K9/28; A61K31/137; A61K9/20;	🗋 EP1027887
	A61K9/28 ; A61K31/137 ; (IPC1-7): A61K31/137	MO9922724
- european:	A61K9/20H6B; A61K9/20H6F2; A61K9/28H6B2;	ີງ WO9847491
	A61K9/28H6F2; A61K31/137	Ti WO9427589
	AOTN9/20HOF2, AOTN31/13/	
Application number	" WO2002IB00001 20020103	US4252786
Priority number(s):	WO2002IB00001 20020103	

Report a data error here

Also published as:

Abstract of WO03055475

Patent number:

WO03055475

A solid controlled release pharmaceutical formulation for once daily administration comprises a core comprising venlafaxine, polyvinylpyrrolidone, a low viscosity hydrophilic polymer and a high viscosity hydrophilic polymer, and a polymeric coating comprising a water high permeable polymer, and a water low permeable polymer. The invention further relates to a process for the preparation of a solid controlled release pharmaceutical formulation comprising the steps of dissolving venlafaxine and ployvinylpyrrolidone in an organic solvent, applying the resulting solution onto low viscosity polymer, homogeneously mixing the obtained granulate with a high viscosity polymer, and compressing the granulate to obtain a core which is then coated with a polymeric coating comprising a water high permeable polymer and a water low permeable polymer.

Data supplied from the esp@cenet database - Worldwide